Latest Clinical News

Venclexta Significantly Reduces Cancer Progression in Chronic Lymphocytic Leukemia (03-22-2018)

CancerConnect News: Venclexta (venetoclax) plus Rituxan (rituximab) significantly reduces the risk of cancer progression or death at two years, compared with Treanda (bendustamine) plus Rituxan in the treatment of chronic lymphocytic leukemia that has... Continue Reading

CancerConnect – Online Support & Networking for Cancer Patients (03-21-2018)

Social networking sites are rapidly growing, giving patients with cancer a place to connect with others. On line social groups on Facebook, discussion boards, and peer to peer networking connections have become widely available and serve some specific... Continue Reading

At-home Genetic Testing may be Convenient, but it isn’t Complete (03-20-2018)

March 14, 2018   Home delivery for everything from fresh produce to custom-selected clothing has become a way of life for many Americans. While most home-delivery conveniences are generally... Continue Reading

It’s in the Genes: Genetic Testing for Ovarian Cancer  (03-15-2018)

What your DNA reveals and why it’s worth knowing CancerConnect News: Ovarian cancer is often dubbed as the “silent killer” of women. The symptoms are vague—including bloating, fatigue, irregular bleeding, frequent urination, and back pain1 —making... Continue Reading

CRISPR Enhances Cancer Immunotherapy (03-14-2018)

Gene editing expands reach of therapeutic T cells, in mice CancerConnect News: Last year, the Food and Drug Administration approved the first cellular immunotherapies to treat cancer. These therapies involve collecting a patient’s own immune cells —... Continue Reading

FDA Approval for Verzenio™ as Initial Treatment for Advanced Breast Cancer (03-12-2018)

CancerConnect News: The U.S. Food and Drug Administration (FDA) has approved VerzenioTM (abemaciclib) in combination with an aromatase inhibitor (AI) as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor-positive... Continue Reading

Darzalex-Effective Treatment for Smoldering Multiple Myeloma (03-7-2018)

CancerConnect News: The use of Darzalex (daratumumab) in smoldering myeloma may be effective in delaying the time to disease progression. These results were presented at the 2017 annual meeting of the American Society of Hematology (ASH). Multiple myeloma... Continue Reading

Pamrevlumab Awarded “Fast Track” Development Status for Treatment of Patients with Locally Advanced Pancreatic Cancer (03-5-2018)

CancerConnect News: The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the anti-CTGF antibody, pamrevlumab, for the treatment of patients with locally advanced unresectable pancreatic cancer. This follows review of the... Continue Reading

Managing a rare cancer (03-1-2018)

Managing a rare cancer diagnosis presents unique challenges. One survivor shares her tips for navigating the sometimes-murky waters. CancerConnect News: Happy New Year: January 7  (the day I became really special). On January 7, I became really special.... Continue Reading

Addition of the Precision Cancer Medicine Adcetris Reduces the Risk of Treatment Failure in Advanced Hodgkin Lymphoma (03-1-2018)

CancerConnect News: Patients with advanced Hodgkin lymphoma (HL) who were treated with a multi-drug regimen that included the precision cancer medicine Adcetris (brentuximab vedotin) had a 23-percent reduction in the risk of disease progression, death,... Continue Reading

Larotrectinib Demonstrates 76 Percent Response Rate in TRK Fusion Cancers Including Pancreatic Cancer (02-28-2018)

CancerConnect News: Clinical data from three ongoing larotrectinib (LOXO-101) clinical trials in patients whose tumors harbor tropomyosin receptor kinase (TRK) fusions demonstrating a 76 percent confirmed objective response rate across tumor types, were... Continue Reading

Keytruda Improves Survival of Advanced Bladder Cancer (02-26-2018)

CancerConnect News: Patients with recurrent urothelial cancer lived longer when they received Keytruda (pembrolizumab) compared to chemotherapy as second-line treatment, according to long-term follow of a clinical trial presented at the Genitourinary... Continue Reading

Next Page »